Abstract
A vulnerable plaque is an atheromatic plaque with specific morphological characteristics, mainly presented as an unstable collection of white blood cells and lipids in the wall of an artery. It is of great importance to adequately recognize and treat this entity before its rupture, before the initiation of an acute coronary syndrome. The search of the location of future plaque ruptures or plaque erosions is an important area of cardiovascular research. Systemic therapy, including use of statins, targets the vulnerable patient. However, adverse events cannot be completely eliminated with the appropriate application of systemic therapies and this has given rise to efforts for evolution of local or regional therapies of the vulnerable plaques to prevent future events. Recently drug eluting stents dedicated to vulnerable plaques have been developed, aiming in the local stabilization of the vulnerable plaque.
Keywords: Vulnerable plaque, optical coherence tomography, coronary artery disease, Eluting Stents, atheromatic plaque, acute coronary syndrome, plaque ruptures, plaque erosions, cardiovascular research, statins
Current Pharmaceutical Design
Title: Drug Eluting Stents for Vulnerable Plague
Volume: 16 Issue: 36
Author(s): Konstantinos Toutouzas, Andreas Synetos and Christodoulos Stefanadis
Affiliation:
Keywords: Vulnerable plaque, optical coherence tomography, coronary artery disease, Eluting Stents, atheromatic plaque, acute coronary syndrome, plaque ruptures, plaque erosions, cardiovascular research, statins
Abstract: A vulnerable plaque is an atheromatic plaque with specific morphological characteristics, mainly presented as an unstable collection of white blood cells and lipids in the wall of an artery. It is of great importance to adequately recognize and treat this entity before its rupture, before the initiation of an acute coronary syndrome. The search of the location of future plaque ruptures or plaque erosions is an important area of cardiovascular research. Systemic therapy, including use of statins, targets the vulnerable patient. However, adverse events cannot be completely eliminated with the appropriate application of systemic therapies and this has given rise to efforts for evolution of local or regional therapies of the vulnerable plaques to prevent future events. Recently drug eluting stents dedicated to vulnerable plaques have been developed, aiming in the local stabilization of the vulnerable plaque.
Export Options
About this article
Cite this article as:
Toutouzas Konstantinos, Synetos Andreas and Stefanadis Christodoulos, Drug Eluting Stents for Vulnerable Plague, Current Pharmaceutical Design 2010; 16 (36) . https://dx.doi.org/10.2174/138161210794454914
DOI https://dx.doi.org/10.2174/138161210794454914 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Review of Some Recent Patents on the Large-Eddy Simulation Technique in Turbulence
Recent Patents on Mechanical Engineering Patent Selections:
Recent Patents on Cardiovascular Drug Discovery Breaking the Barrier in Stroke: What Should we Know? A Mini-Review
Current Pharmaceutical Design Endovascular Versus Open Abdominal Aortic Aneurysm: Best Decision
Current Pharmaceutical Design Encephalopathy: A Vicious Cascade Following Forebrain Ischemia and Hypoxia
Central Nervous System Agents in Medicinal Chemistry Chymase Inhibitor As a Novel Therapeutic Strategy for Anti-Vascular Remodeling
Vascular Disease Prevention (Discontinued) The Shift in the “Paradigm” of the Pharmacology of Hypertension
Current Topics in Medicinal Chemistry Implications of microRNAs in the Pathogenesis of Atherosclerosis and Prospects for Therapy
Current Drug Targets The Genetics of Small-Vessel Disease
Current Medicinal Chemistry High Dose Immunoglobulin (IVIG) May Reduce the Incidence of Langerhans Cell Histiocytosis (LCH)-Associated Central Nervous System Involvement
CNS & Neurological Disorders - Drug Targets Is Peri-Operative Isolated Systolic Hypertension (ISH) a Cardiac Risk Factor?
Current Cardiology Reviews Porphyrin-Photosensitized Processes: Their Applications in the Prevention of Arterial Restenosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Bridging Innate Immunity and Myocardial Ischemia/Reperfusion Injury: The Search for Therapeutic Targets
Current Pharmaceutical Design Epigenetics in the Cerebrovascular System: Changing the Code without Altering the Sequence
Current Neurovascular Research The effect of Endovascular Aneurysm Repair on Renal Function in Patients Treated for Abdominal Aortic Aneurysm
Current Pharmaceutical Design Vascular Effects of Estrogenic Menopausal Hormone Therapy
Reviews on Recent Clinical Trials Perioperative Management of Intracranial Aneurysm and Subarachnoid Hemorrhage
Current Pharmaceutical Design The Role of EC-IC Bypass in Critical Cerebral Hemodynamics of Different Origin
Current Hypertension Reviews Inflammation in Coronary Artery Disease and Acute Myocardial Infarction - is the Stage Set for Novel Therapies?
Current Pharmaceutical Design Impact of Tobacco Smoking on Lipid Metabolism, Body Weight and Cardiometabolic Risk
Current Pharmaceutical Design